Literature DB >> 15565383

[Interferon therapy of multiple sclerosis. Synopsis of various dosage forms].

S Jarius1, R Hohlfeld.   

Abstract

In addition to the clinical efficacy, which is similar for the three approved interferon-beta preparations, the compliance and acceptance of interferon therapy are determined by several other factors. These include the mode of application, formulation, storing conditions, and injection methods. Some of these factors have been modified recently. In this article we provide a synopsis of the current application formats of the different interferon-beta preparations, and discuss the respective advantages and drawbacks.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15565383     DOI： 10.1007/s00115-004-1834-0

Source DB:  PubMed          Journal:  Nervenarzt        ISSN： 0028-2804            Impact factor:   1.214


  15 in total

Review 1.  [Interferon therapy of multiple sclerosis. A question of the correct dose?].

Authors:  R Hohlfeld
Journal:  Nervenarzt       Date:  2001-02       Impact factor: 1.214

2.  [Immunotherapy of multiple sclerosis. Consensus and controversies].

Authors:  R Hohlfeld
Journal:  Nervenarzt       Date:  1999-04       Impact factor: 1.214

3.  Local pain during REBIF injection is not due to acidic pH.

Authors:  M Buttmann; M Goebeler; P Rieckmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

Review 4.  Multiple sclerosis: side effects of interferon beta therapy and their management.

Authors:  E U Walther; R Hohlfeld
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

5.  Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.

Authors:  H Panitch; D S Goodin; G Francis; P Chang; P K Coyle; P O'Connor; E Monaghan; D Li; B Weinshenker
Journal:  Neurology       Date:  2002-11-26       Impact factor: 9.910

Review 6.  [Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002].

Authors:  P Rieckmann; K V Toyka
Journal:  Nervenarzt       Date:  2002-06       Impact factor: 1.214

7.  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

Review 8.  [Diagnosis and treatment of multiple sclerosis. Update, 2003].

Authors:  S Jarius; R Hohlfeld; R Voltz
Journal:  MMW Fortschr Med       Date:  2003-05-26

9.  A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.

Authors:  J Theodore Phillips; George Rice; Elliot Frohman; Luc Vande Gaer; Thomas Scott; Judith Haas; Eric Eggenberger; Mark S Freedman; William Stuart; Luis Cunha; Lawrence Jacobs; Joel Oger; Douglas Arnold; T Jock Murray; Mary DiBiase; Vijay Jethwa; Susan Goelz
Journal:  Clin Ther       Date:  2004-04       Impact factor: 3.393

10.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.